A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Regenxbio Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 134,190 shares of RGNX stock, worth $1.25 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
134,190
Previous 106,284 26.26%
Holding current value
$1.25 Million
Previous $2.24 Million 29.88%
% of portfolio
0.08%
Previous 0.12%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$11.51 - $21.53 $321,198 - $600,816
27,906 Added 26.26%
134,190 $1.57 Million
Q1 2024

Apr 17, 2024

BUY
$12.17 - $24.61 $396,547 - $801,892
32,584 Added 44.21%
106,284 $2.24 Million
Q4 2023

Jan 10, 2024

BUY
$12.89 - $20.82 $171,901 - $277,655
13,336 Added 22.09%
73,700 $1.32 Million
Q3 2023

Oct 27, 2023

SELL
$16.46 - $19.99 $89,295 - $108,445
-5,425 Reduced 8.25%
60,364 $993,000
Q2 2023

Aug 09, 2023

SELL
$17.23 - $21.71 $628,447 - $791,850
-36,474 Reduced 35.67%
65,789 $1.32 Million
Q1 2023

Apr 20, 2023

SELL
$18.08 - $24.55 $54,456 - $73,944
-3,012 Reduced 2.86%
102,263 $1.93 Million
Q4 2022

Jan 12, 2023

BUY
$20.4 - $24.73 $232,437 - $281,773
11,394 Added 12.14%
105,275 $2.39 Million
Q3 2022

Nov 14, 2022

BUY
$22.29 - $35.04 $97,786 - $153,720
4,387 Added 4.9%
93,881 $2.48 Million
Q2 2022

Jul 19, 2022

BUY
$19.35 - $35.04 $415,773 - $752,904
21,487 Added 31.6%
89,494 $2.21 Million
Q1 2022

Apr 26, 2022

BUY
$24.62 - $34.31 $351,081 - $489,260
14,260 Added 26.53%
68,007 $2.26 Million
Q4 2021

Feb 14, 2022

BUY
$30.19 - $40.28 $690,113 - $920,760
22,859 Added 74.01%
53,747 $1.76 Million
Q3 2021

Nov 12, 2021

BUY
$29.09 - $45.68 $307,655 - $483,111
10,576 Added 52.07%
30,888 $1.3 Million
Q2 2021

Aug 13, 2021

BUY
$32.46 - $40.48 $659,327 - $822,229
20,312 New
20,312 $789,000

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $404M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Hennion & Walsh Asset Management, Inc. Portfolio

Follow Hennion & Walsh Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.